New EU Market Hopefuls Await Their Fate; EMA Re-Adopting Zynteglo Opinion

Sponsors of a raft of new products will find out this week if the European Medicines Agency’s medicines evaluation committee, the CHMP, is convinced the therapies are ready for marketing.

Concept of national healthcare system - EU - European Union
New medicines are being considered for pan-EU approval • Source: Shutterstock

Novo Nordisk’s long-acting Factor VIII replacement therapy for hemophilia A, turoctocog alfa pegol, is among 14 new products that are up for an opinion by the European Medicines Agency’s drugs evaluation committee, CHMP, this week on potential pan-EU approval.

In addition, the positive opinion that the CHMP issued last month for bluebird bio’s first-of-a-kind gene therapy for transfusion-dependent...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography